SEC Tracker
Get the app

Alumis ALMS

Alumis FY 2024: net loss $294.2M; diluted EPS −$10.38

Form
10-K
Filed
Period
Importance
Notable
Document
10-K
Exhibit 10.9
Material contract

Key figures from this report

These are the numbers Alumis reported for the year ended Dec 31, 2024, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Net income−$294.2MNo year-earlier figure tagged10-K income statement, on EDGAR
  2. Diluted EPS−$10.38No year-earlier figure tagged10-K income statement, on EDGAR
  3. Cash and cash equivalents$169.5MNo year-earlier figure taggedCash and equivalents only; the company page adds short-term investments.10-K balance sheet, on EDGAR
  4. Cash from operations−$255.1MNo year-earlier figure tagged10-K cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when Alumis files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Crescent Biopharma CBIO public float $177M, Jun 30, 2025
  2. Editas Medicine EDIT public float $191M, Jun 30, 2025
  3. Omeros OMER public float $172M, Jun 30, 2025
  4. Palvella Therapeutics PVLA public float $197M, Jun 30, 2025
  5. Lexicon Pharmaceuticals LXRX public float $170M, Jun 30, 2025